The human cationic antimicrobial protein LL-37 is a multifunctional host defense peptide with a wide range of immunomodulatory activities. Previous work has shown that LL-37 exerts both pro-and antiinflammatory effects. The role of mitochondria in the skin inflammatory effects of LL-37 has not been well studied. Therefore, our aim was to investigate the immunomodulatory effect of LL-37 in HaCaT cells and to delineate the underlying mechanisms related to mitochondrial function. Immunohistochemistry results from tissue microarrays showed strong cytoplasmic LL-37 staining in inflammatory cells in chronic dermatic inflammation. Using exogenous LL-37 stimulation and LL-37 knockdown and overexpression, LL-37 was demonstrated to dramatically reduce the mRNA levels and protein secretion of inflammatory cytokines including IL-6, IL-8, IL-1␣ and tumor necrosis factor-␣ (TNF-␣), which are induced by lipopolysaccharides (LPS). The anti-inflammatory effects of LL-37 are dependent upon its ability to increase mitochondrial biogenesis and to maintain mitochondrial homeostasis. Furthermore, we observed that LL-37 enhances the LPS-induced phosphorylation of extracellular signal-regulated kinase (ERK1/2) and mammalian target of rapamycin (mTOR). The mTOR inhibitor rapamycin can neutralize the protective effects of LL-37 on mitochondria. In conclusion, these results suggest that high LL-37 expression levels correlate with chronic skin inflammation; mitochondrial dysfunction occurs in HaCaT cells during inflammation; and LL-37 attenuates inflammatory impairment by stimulating mitochondrial biogenesis and protecting mitochondrial function, which are dependent upon mTOR signaling. These findings provide new insights into targeting mitochondria with LL-37 to prevent skin inflammatory reactions.
Introduction
Mammalian skin, particularly the epidermis, is largely composed of keratinocytes and provides an essential defensive barrier against external insults (Athar, 2002) . The human cationic antimicrobial protein hCAP18/LL-37 is the only human cationic cathelicidin peptide, and its C-terminal peptide, LL-37, has been shown to be multifunctional (Hancock and Diamond, 2000; Zanetti, 2004) .
Previous work has demonstrated that LL-37 may exaggerate inflammatory responses and lead to disease. Excessive LL-37 is associated with rosacea and drives inflammation and abnormal blood vessel growth through cell activation mechanisms (Yamasaki et al., 2007) . The high levels of LL-37 in psoriasis may also promote undesirable inflammation (Gilliet and Lande, 2008) . LL-37 can indirectly promote the recruitment of inflammatory cells by inducing bronchial epithelial cells to release interleukin-8 (IL-8) (Filewod et al., 2009) . LL-37 can also augment the secretion of IL-6 and IL-10 induced by the proinflammatory cytokine IL-1␤ in myeloid cells (Yu et al., 2007) .
LL-37 can have opposing effects because it can also be antiinflammatory. For example, LL-37 dramatically suppresses tumor necrosis factor ␣ (TNF-␣) production induced by the stimulation of human monocytes or macrophage cell lines with lipopolysaccharide (LPS) or lipoteichoic acid (LTA) in vitro (Mookherjee et al., 2006; Scott et al., 2000) . LL-37 also reduces LPS and interferon ␥ (IFN-␥) responses in human peripheral blood mononuclear cells (PBMCs) and mouse splenic B cells . LL-37 selectively reduces proinflammatory macrophage responses (Brown et al., 2011) and inhibits dsRNA/TLR3-induced TNF-␣ and IL-8 in keratinocytes (Chen et al., 2013) . Consistent with these suppressive effects in vitro, LL-37 is protective in mouse models of LPS-induced sepsis (Scott et al., 2002) . In addition, LL-37 up-regulates formyl peptide receptor-like 1 (FPRL1) expression (Carretero et al., 2008) and inhibits apoptosis by activating the cyclooxygenase 2 (COX-2) pathway in HaCaT cells (Chamorro et al., 2008) . LL-37 expression can be regulated by hypoxia-inducing factor 1 ␣ (HIF-1␣) Peyssonnaux et al., 2008) . Therefore, the contrasting effects of LL-37 on inflammation may depend on multiple factors, including peptide concentration, processing time, and disease and cell type.
Autophagy is a crucial component of the cellular stress adaptation response (White et al., 2010) , and its pathways have been demonstrated to play a key role in fine-tuning inflammatory responses in keratinocytes (Fésüs et al., 2011) . Mitochondria play a central role in the initiation of inflammasomes and other inflammatory pathways (Green et al., 2011) . Therefore, it is likely that the accumulation of damaged mitochondria is an important cause of inflammation. Stimulation of autophagy may mediate cytoprotective and anti-inflammatory effects, which may be at least partially ascribed to the removal of dysfunctional mitochondria (Green et al., 2011) . Accumulating data have demonstrated that mammalian target of rapamycin (mTOR) regulates autophagy (Wullschleger et al., 2006) . Tuberous sclerosis complex (TSC), the ribosomal p70S6 kinase (p70S6 K), and initiation factor 4E-binding protein 1 (4E-BP1) are the most extensively studied targets of mTOR (Harris and Lawrence, 2003; Inoki et al., 2002; Jacinto and Hall, 2003; Potter et al., 2002) .
Consequently, we postulated that impairment of mitochondrial function by inflammatory mediators is a mechanism by which skin inflammation occurs. In the present study, we sought to understand the relationship between LL-37 and skin inflammation and to delineate the underlying mechanisms. We first applied immunohistochemistry to study LL-37 protein expression in chronic dermatic inflammation that was not psoriasis or atopic dermatitis using skin tissue microarrays (TMAs). Second, LL-37 knockdown and overexpression studies were performed in HaCaT cells. Third, the effect of exogenous LL-37 stimulation and LL-37 knockdown and overexpression on inflammatory markers, mitochondrial function, homeostasis, and autophagy were examined. Finally, the underlying mechanisms of the effects of LL-37 on signaling pathways involving extracellular signal-regulated kinase (ERK) and TSC2/mTOR were investigated.
Materials and methods

Antibodies and reagents
The peptide LL-37 (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRN-LVPRTES) was purchased from Anaspec (Fremont, CA). All Table 1 Primers for mRNA quantitation using quantitative real-time PCR. TNF-␣  TCCTTCAGACACCCTCAACC AGGCCCCAGTTTGAATTCTT  IL-6  AAGCCAGAGCTGTGCAGATGAGTA TGTCCTGCAGCCACTGGTTC  IL-8  GTCCTTGTTCCACTGTGCCT GCTTCCACATGTCCTCACAA  IL-1␣  TGGCTCATTTTCCCTCAAAAGTTG AGAAATCGTGAAATCCGAAGTCAAG  IL-1␤  CCAGGGACAGGATATGGAGCA TTCAACACGCAGGACAGGTACAG  LL-37 GGCAAGCTTGAGGCAGACATGG GCCGGATCCAGGGTAGGGAACAC ␤-Actin TGGCACCCAGCACAATGAA CTAAGTCATAGTCCGCCTAGAAGCA other chemicals were analytical purity-grade reagents from Sigma-Aldrich (St. Louis, MO) and local vendors.
Forward Reverse
TMA and immunohistochemistry
Skin TMA sections (Cybrdi, Shanxi ChaoYing, Xi'an, China), which included 80 samples (12 squamous cell carcinoma, 12 basal cell carcinoma, 12 malignant melanoma, 10 condyloma acuminatum, 6 basal cell papilloma, 1 cyst, 1 verruca vulgaris, 6 hyperplasia, 5 chronic inflammation, 5 cancer-adjacent tissue, 5 cancer-adjacent normal dermatic tissue, and 5 normal dermatic tissue) were assayed as previously described (Park et al., 2008) (Table 2) . Briefly, the anti-LL-37 primary antibody (Santa Cruz Biotechnology, Santa Cruz, CA) was applied followed by the Polink-2 plus ® polymer HRP detection system (Zhongshan Jinqiao, Beijing, China). Immunohistochemical staining was evaluated as described previously (Möllerström et al., 2010) .
Cell culture and stable cell lines
The normal human HaCaT cell line was obtained from the Chinese Academy of Sciences (Kunming, China) and cultured in DMEM supplemented with 10% fetal calf serum. The complete LL-37 region was amplified by reverse transcription PCR from HaCaT cells using the primers shown in Table 1 and inserted into the BamHI sites of pEGFP-C3 (Clontech, Hampshire, UK), creating LL-37-EGFP. The plasmid was verified by sequence analysis to confirm the absence of mutations. The stable LL-37-EGFP and NC-EGFP HaCaT cell lines were constructed as previously described (Takeichi et al., 2010) . Transfected cells were subcultured in the presence of 600 ng/ml G418 (Invitrogen, Carlsbad, CA).
Cell fixation and immunofluorescence
LL-37 and NC-EGFP HaCaT cells were cultured on coverslips, fixed with 4% paraformaldehyde (Sigma-Aldrich) for 20 min, and permeabilized with 0.1% Triton X-100/PBS. After blocking in 5% BSA/PBS, the cells were incubated with a primary antibody against LL-37 for 2 h, washed, and then incubated with the appropriately conjugated secondary antibody (Beyotime, Jiangsu, China) for 60 min. Nuclear staining was performed using 4,6-diamidino-2-phenylindole (DAPI; Sigma). Immunofluorescence was visualized using a confocal laser scanning microscope (Zeiss, Oberkochen, Germany).
siRNA directed against LL-37 expression in HaCaT cells
Three siRNA oligonucleotides targeting LL-37 and designed by GenePharma (Shanghai, China) were evaluated, and one (sense:
5 -GGAAAUCUAAAGAGAAGAUTT-3 , antisense: 5 -AUCUUCUCUUUAGAUUUCCTT-3 ) that demonstrated maximum LL-37 knockdown activity in HaCaT cells (transfected for 48 h) was applied. HaCaT cells were cultured in 6-well plates to 40-50% confluence and then cultured in DMEM. The cells were transfected 
with the LL-37-siRNA or NC-siRNA using Lipofectamine 2000 according to the manufacturer's instructions.
JC-1 assay for mitochondrial membrane potential ( « )
« was assessed as previously described (Feng et al., 2011) . Briefly, cells were incubated with 5 mol/L 5,5 ,6,6 -tetrachloro-1,1 ,3,3 -tetraethylbenzimidazolyl-carbocyanine iodide (JC-1) (Invitrogen) at 37 • C for 60 min. The fluorescence-labeled cells were washed with PBS and analyzed on a microplate fluorometer (Fluoroskan Ascent; Thermo Fisher Scientific, Waltham, MA, USA) at 488 nm excitation and 535 and 590 nm emission to measure green and red JC-1 fluorescence, respectively. The ratio of fluorescence at 590 nm versus 535 nm emission was used for quantitating « .
RNA isolation and quantitative reverse transcription PCR
Quantitative PCR was performed as previously described (Hao et al., 2010) . Total RNA was extracted using TRIzol reagent (Invitrogen), and reverse transcription was performed using a Takara RNA PCR kit (Takara, Dalian, China) following the manufacturer's instructions. Quantitative PCR was performed using SYBR Green Premix Ex Taq (Takara) on a real-time PCR system (Eppendorf, Germany). The relative expression ratio was calculated using the 2 − CT method. The specific primers, which were synthesized by Baiaoke Biotech (Beijing, China), are shown in Table 1 .
ELISA for cytokines
TNF-␣, IL-6, IL-8, IL-1␣, and IL-1␤ levels in culture supernatants were measured using an ELISA kit purchased from Excell Biology, Inc. (Shanghai, China). Briefly, supernatants were added to 96-well plates coated with a specific monoclonal antibody. After exposure to medium, the assay plates were sequentially exposed to biotin-conjugated anti-cytokine antibodies and detected with a streptavidin-peroxidase-conjugated anti-rabbit antibody. The plate was developed using a 3,3 ,5,5 tetramethylbenzidine (TMB) and the optical density of each well was determined at 450 nm on a microplate reader (Bio-Rad, Hercules, CA).
Western blot assays
Western blots were performed as previously described (Feng et al., 2011) . Briefly, blocked membranes were incubated with anti-PGC-1␣, anti-Mfn1, anti-Mfn2, anti-DRP1, anti-␤-actin, or anti-␣-tubulin (Santa Cruz); anti-OPA1 (BD Biosciences, San Jose, CA); anti-OxPhos Complex I, anti-OxPhos Complex II, anti-OxPhos Complex III or anti-Complex V (Invitrogen); anti-LL-37 (Abgent, San Diego, CA); or anti-Beclin1, anti-LC3B, anti-Atg 7, anti-mTOR, antip-mTOR (Ser2448), anti-p-ERK1/2 (Thr202/Tyr204) or anti-ERK2 (Cell Signaling Technology, Beverly, MA) at a dilution of 1:1000 or 1:2000 followed by chemiluminescent ECL detection (Pierce, Rockford, IL).
Statistical analysis
All data are representative of at least three independent experiments. Data are presented as means ± S.D. Statistical significance was calculated with GraphPad Prism 5 statistical software, with P values <0.05 considered significant.
Results
High levels of LL-37 protein expression in chronic dermatic inflammation and hyperplasia of dermatic tissue of squamous epithelium
Skin TMAs were used to compare the expression levels of LL-37. One case missed TMA processing and was excluded. A total of 79 cases were analyzed.
Immunohistochemical results showed that in 5 cases of chronic dermatic inflammation and 6 cases of hyperplasia of dermatic tissue of squamous epithelium, Positive LL-37 peptide shows as claybank particles which were mainly distributed in the cytoplasm in epidermal cells and inflammatory cells (Fig. 1A and  B) . In the epidermal layer, LL-37 was mainly localized to the stratum spinosum, whereas in the dermal layer, LL-37 was mainly expressed in inflammatory cells and vascular endothelial cells. In 5 cases of normal dermatic tissue that was not adjacent to cancer sites and 5 cases of cancer-adjacent normal dermatic tissue, LL-37 was mainly expressed in the epidermal stratum corneum. In both cases, the protein was primarily localized to the cytoplasm (Fig. 1C and D) . Inflammatory cells from chronic dermatic inflammation and hyperplasia of dermatic tissue of squamous epithelium exhibited significantly enhanced staining for LL-37 compared with samples from non-cancer-adjacent normal dermatic tissue and cancer-adjacent normal dermatic tissue (P < 0.05). Furthermore, we observed that in squamous cell carcinoma, basal cell carcinoma, and malignant melanoma, LL-37 expression was mainly cytoplasmic and significantly increased compared with non-cancer-adjacent normal dermatic tissue or cancer-adjacent normal dermatic tissue (P < 0.05, supplementary Fig. 1) . 
Characterization of LL-37 knockdown and overexpression in HaCaT cells
To investigate the function of LL-37 in dermatic tissue, a small interfering RNA (siRNA) against human LL-37 was used to knock down LL-37 expression; the level of LL-37 mRNA was measured 48 h later in immortalized human epithelial HaCaT cells. Compared with the negative control (NC) siRNA and non-transfected HaCaT cells, a significant decrease in LL-37 mRNA levels after LL-37-siRNA transfection was observed ( Fig. 2A) . In addition, HaCaT cells constitutively expressing LL-37 (LL-37-enhanced green fluorescent protein (EGFP) cells) or EGFP alone (NC-EGFP cells) were generated. LL-37 mRNA was more abundant in LL-37-EGFP HaCaT cells than in non-transfected HaCaT cells or NC-EGFP cells as determined by quantitative RT-PCR (Fig. 2B) . Consistent with LL-37 mRNA overexpression, western blots and immunofluorescent staining demonstrated that the LL-37 signal from LL-37-EGFP HaCaT cells was enhanced compared with NC-EGFP cells (Fig. 2C  and D) .
LL-37 functionally suppresses inflammatory cytokine expression
To determine the function of LL-37 in the inflammatory response, LPS was used to induce an inflammatory response, and LL-37 levels were monitored in a dose-dependent manner. As shown in Fig. 3A and B, 24 h after exposure to LPS, HaCaT cells exhibited marked inflammatory responses as evidenced by increases in the inflammatory markers TNF-␣, IL-8, and IL-1␣ measured by quantitative RT-PCR and enzyme-linked immunosorbent assay (ELISA). LL-37 (1.1 M) treatment attenuated IL-8, TNF-␣, and IL-1␣ production. A high dose of LL-37 (2.2 M) reduced the expression of inflammatory cytokines in the presence of 100 ng/ml LPS.
Silencing LL-37 led to further increases in TNF-␣, IL-8, and IL-6 mRNA and protein accumulation after LPS stimulation ( Fig. 3C  and D) . Next, the effect of LL-37 overexpression on the expression of inflammatory cytokines was analyzed. LL-37-EGFP cells exhibited lower levels of inflammatory cytokine expression at both the mRNA and protein levels compared with the control NC-EGFP Immunofluorescence analysis of LL-37 overexpression. Cells were stained for enhanced green fluorescent protein (EGFP) (green) and anti-LL-37 (red), and the nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI) (blue). The data shown are representative of three independent experiments. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) cells (Fig. 3E and F) , suggesting a protective role of LL-37 against inflammation.
LL-37 increases mitochondrial function and regulates mitochondrial homeostasis during inflammation
Recent studies have revealed that mitochondrial dysfunction plays a key role in the inflammatory response (Cordero et al., 2013; Joven, 2013) . To investigate the effect of LL-37 on mitochondrial function, the protein levels of peroxisome proliferator-activated receptor gamma coactivator-1 ␣ (PGC-1␣), the key regulator of mitochondrial biogenesis, and mitochondrial respiratory chain enzyme complexes were determined in LL-37 overexpressing and knockdown cells. As expected, LPS induced the loss of accumulation of complexes II, III and V; however, pretreatment with 1.1 or 2.2 M LL-37 efficiently prevented these losses ( Fig. 4A and B) . Unlike the protein levels of complexes II, III, and V, complex I and IV levels were unaffected by LL-37 pretreatment (data not shown).
Knockdown of LL-37 and the addition of LPS to LL-37 knockdown cells led to a significant inhibition of the expression of complexes I, II, and V compared with NC-siRNA cells (Fig. 4C and D) . Conversely, LL-37 overexpression led to the increased expression of PGC-1␣ and complexes I and V compared with empty vector control cells ( Fig. 4E and F) .
In addition to regulating the mitochondrial biogenesis of PGC-1␣ and respiratory chain enzyme complexes, mitochondrial fusion and fission are important processes that result in the continuous remodeling of mitochondrial network dynamics (Bo et al., 2010) .
In this study, we further found that LL-37 pretreatment or overexpression significantly inhibited the LPS-induced increase in the mitochondrial fusion-related proteins Mfn2 and OPA1 and the mitochondrial fission-related protein DRP1 (Fig. 4A, B, E and F) . Upon LPS stimulation, LL-37 knockdown led to increases in the expression of Mfn2 and DRP1 (Fig. 4C and D) . Therefore, we confirmed that LL-37 can regulate mitochondrial metabolism in HaCaT cells via various mechanisms.
LL-37 down-regulates the expression of autophagy-related proteins
Dysfunctional mitochondria are usually eliminated by autophagy, allowing cells to maintain healthy mitochondrial metabolism (Wang and Klionsky, 2011) . Next, we examined the function of LL-37 in regulating autophagy. Treating HaCaT cells with LPS alone significantly increased the endogenous accumulation of Beclin1 and LC3B. Pretreatment with LL-37 dramatically inhibited LPS-induced Beclin1 and LC3B accumulation (Fig. 5A and  B) . These data partially confirm findings from previous studies that have demonstrated that treating HaCaT cells with LPS robustly increases punctate LC3 expression and LC3-II band intensities .
Additionally, transfecting HaCaT cells with an LL-37-specific siRNA dramatically increased LPS-induced Beclin1 and LC3B expression ( Fig. 5C and D) . In contrast, upon LPS stimulation, LL-37-overexpressing cells showed decreases in LC3B and Atg7 compared with the control NC-EGFP cells (Fig. 5E and F) . These results suggest Fig. 3 . Effect of exogenous LL-37 administration, LL-37 knockdown and overexpression on the lipopolysaccharide (LPS)-induced mRNA and protein expression of inflammatory cytokines using qRT-PCR and enzyme-linked immunosorbent assay (ELISA). (A, B) HaCaT cells were exposed to LPS for 24 h after preincubation with or without LL-37 for 24 h. (C, D) HaCaT cells were treated with LPS for 24 h after transfection with an LL-37 siRNA or NC-siRNA for 48 h. (E, F) Stable HaCaT cells were exposed to LPS for 24 h. Error bars represent SD. *P < 0.05, **P < 0.01 and ***P < 0.001. 0, control; 1.1 or 2.2, control with 1.1 or 2.2 M LL-37, respectively; 100 or 1000, control with 100 or 1000 ng/ml LPS treatment, respectively; 100 + 1.1 or 100 + 2.2, control with 100 ng/ml LPS after preincubation with 1.1 or 2.2 M LL-37, respectively; 1000 + 1.1 or 1000 + 2.2, control with 1000 ng/ml LPS after preincubation with 1.1 or 2.2 M LL-37, respectively; veh-si, vehicle-siRNA; veh-si-100 or veh-si-1000, vehicle-siRNA cells with 100 or 1000 ng/ml LPS treatment, respectively; LL-si, LL-37-siRNA; LL-si-100 or LL-si-1000: LL-37-siRNA HaCaT cells with 100 or 1000 ng/ml LPS treatment, respectively; veh, vehicle; veh-100 or veh-1000, vehicle with 100 or 1000 ng/ml LPS treatment, respectively; LL, LL-37; LL-100 or LL-1000, LL-37-EGFP HaCaT cells with 100 or 1000 ng/ml LPS treatment, respectively.
that LL-37 attenuates the increased autophagy caused by inflammatory responses.
Neutralized LL-37 protects against the LPS-induced decrease in « via enhancement of mTOR activation
To further understand the signaling pathways upstream of the LL-37 effect, we examined a potential role for LL-37 in LPSinduced ERK and mTOR activation. LL-37 pretreatment enhanced LPS-induced ERK and mTOR activation in HaCaT cells (Fig. 6A and  B) . LL-37 overexpression led to higher levels of ERK and mTOR activation in LL-37-EGFP HaCaT cells after LPS stimulation compared with NC-EGFP cells (Fig. 6E and F) . LL-37 knockdown consistently inhibited the phosphorylation of ERK and mTOR ( Fig. 6C and D) .
The ERK inhibitor U0126 and the mTOR inhibitor rapamycin were added to cells treated with exogenous LL-37 or cells overexpressing LL-37. We found that both U0126 and rapamycin decreased LPS-induced ERK and mTOR phosphorylation (Fig. 6A , B, E and F). Because inflammation induces mitochondrial dysfunction in vitro and in vivo (Hunter et al., 2007) and « is an important index of mitochondrial function, the effects of U0126 and rapamycin on the LL-37-mediated protection of « in LPS-induced inflammatory response were examined. Rapamycin and LL-37 siRNA but not the ERK inhibitor U0126 neutralized the protective effects of LL-37 and produced a low « (Fig. 6G-I) , indicating that mTOR activation may play an essential role in LL-37-mediated protection against LPS-induced mitochondrial dysfunction.
Discussion
The role of LL-37 has been widely studied in two skin pathologies, atopic dermatitis and psoriasis. Patients with psoriasis express higher levels of LL-37 (Ong et al., 2002) compared with patients with atopic dermatitis. Dombrowski et al. (2011) demonstrated that intracellular LL-37 serves as an anti-inflammatory agent by blocking the DNA-triggered formation of AIM2 inflammasomes in keratinocytes, inhibiting IL-1␤ release. However, several studies have shown that extracellular or endosomal LL-37 enhances TLR9 expression and function in keratinocytes, leading to increased IFN-␣/␤ production (Morizane et al., 2012) . Therefore, understanding the mechanisms that suppress the inflammatory response during skin inflammation may help identify therapeutic targets for treatments that are relevant to multiple inflammatory skin diseases.
In this study, skin TMAs showed that the samples from chronic dermatic inflammation and hyperplasia of dermatic tissue of squamous epithelium had much more intense staining for LL-37 than samples from normal dermatic tissue or cancer-adjacent normal dermatic tissue using immunohistochemistry. We conclude that high LL-37 levels may correlate with chronic skin inflammation. Next, plasmid DNA or siRNA approaches were used to overexpress or knock down the LL-37 gene in HaCaT cells. LL-37 administration or overexpression robustly inhibited inflammatory cytokine secretion during LPS-induced inflammation and demonstrated that LL-37 may exert anti-inflammatory effects. Therefore, LL-37 knockdown led to an increase in TNF-a, IL-8, and IL-6 mRNA and protein accumulation in the absence of LPS and further increased proinflammatory cytokine production in the presence of LPS.
Mitochondrial damage implies a direct cause-and-effect relationship between inflammation and autophagy. The selective degradation of mitochondria is termed mitophagy . This type of selective process is thought to play a crucial role in mitochondrial homeostasis. We found that LL-37 protected mitochondrial function and maintained mitochondrial homeostasis through regulated mitochondrial fusion and fission during LPS-induced inflammation.
In many instances, autophagy controls inflammasome activation and can limit the production of the inflammatory cytokines IL-1␤ and IL-18 (Saitoh et al., 2008) . Autophagy can also inhibit NLRP3 activation by removing ROS-producing mitochondria (Nakahira et al., 2011; Zhou et al., 2011) . In this study, LL-37 administration or overexpression significantly inhibited the expression of autophagy-related proteins, and LL-37 knockdown increased during LPS-induced inflammation, which is consistent with the result that autophagy negatively regulates inflammation. Previous studies have unraveled the TSC2-mTOR signaling pathway in limiting the proinflammatory cytokine production induced by various bacterial stimuli in monocytes, macrophages and primary dendritic cells (Weichhart et al., 2008) . Mitogenactivated protein kinases (MAPKs) are implicated in inflammatory signaling, which facilitates the production of inflammatory mediators (Kaminska, 2005) . ERK may modulate mTOR signaling and contribute to disease progression through the phosphorylation and inactivation of TSC2 (Ma et al., 2005) . To understand the molecular mechanism of the protective effect of LL-37 in LPS-treated HaCaT cells, we analyzed the ERK and mTOR signaling pathways. We found that ERK and mTOR activation were involved after LPS stimulation and that LL-37 pretreatment and overexpression enhanced LPS-induced ERK and mTOR activation in HaCaT cells. The mTOR inhibitor, but not the ERK inhibitor, neutralized the protective effects of LL-37 against LPS, suggesting that mTOR signaling activation is necessary for LL-37's protective effects against LPS-induced inflammation and mitochondrial dysfunction.
Therefore, we have shed light on the high expression levels of LL-37 that correlate with chronic dermatic inflammation and how LL-37 may protect mitochondrial function and mitochondrial homeostasis mechanisms through mTOR signaling in skin inflammation. Moreover, we have identified and provided new insights into how mitochondria can be targeted to prevent skin inflammation.
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